Barclays Downgrades Zealand Pharma Stock on Distant Catalysts

Barclays downgraded Zealand Pharma A/S to Equalweight from Overweight, reducing its price target as heightened competition in the obesity drug market threatens to outpace the company's clinical timeline.

"Barclays downgraded Zealand Pharma to Equalweight from Overweight and lowered its price target to DKK330.00 from DKK425.00," according to Investing.com.

Pipeline Timelines and Eli Lilly Competition

The downgrade stems from concerns that rival drug developers are moving faster in key indications. Barclays noted that Eli Lilly has advanced eloralintide into five Phase 3 studies, positioning the pharmaceutical giant to report pivotal obesity data at least six to 12 months ahead of Zealand Pharma's competing petrelintide candidate.

This potential delay in commercialization places pressure on Zealand Pharma's valuation as investors weigh the speed at which competitors are scaling their late-stage assets. In the GLP-1 and obesity treatment sector, missing a window to establish market share can significantly alter long-term revenue projections.

Survodutide Sales Estimates and Tolerability Debate

Alongside the rating change, Barclays adjusted its financial projections for Zealand Pharma's pipeline. The bank reduced its risk-unadjusted peak sales estimates for survodutide to $2.3 billion from $3.6 billion.

Analysts pointed to a disappointing tolerability profile for survodutide alongside ongoing debate surrounding discontinuation rates and gastrointestinal side effects. Such tolerability hurdles can complicate patient retention in real-world settings, prompting analysts to adopt more conservative forecasting models for upcoming commercial launches.

Jefferies Joins Downgrade Wave Amid Catalyst Vacuum

Barclays is joined by other financial institutions reassessing the Danish biotech firm. Jefferies also downgraded Zealand Pharma's stock rating from Buy to Hold, slashing its price target from DKK 505.00 to DKK 320.00.

Both firms highlighted the absence of major near-term clinical catalysts in the second half of the year. With few major data readouts scheduled to drive momentum in the immediate future, institutional analysts are recalibrating expectations for the stock until clearer pipeline milestones are reached.